Trial Profile
A Randomized, Open-Label, 4-Way Crossover Replicate Design Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jul 2018
Price :
$35
*
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 15 Jun 2018 Results of pooled data from 14 trials, were published in the Journal of Clinical Pharmacology.
- 18 Sep 2014 New trial record